Catalyst Pharmaceuticals (CPRX) 2024 Wells Fargo Healthcare Conference summary

Business overview and key drivers

• Focus on three main products: Firdapse, Agamree, and Fycompa, with emphasis on execution, sales optimization, and lifecycle management.

• Strategic initiatives include business development, buy-and-build, and global partnerships, especially outside the U.S.

• Firdapse is the primary commercial driver, with high teens growth rates in recent quarters.

Intellectual property and litigation

• Firdapse faces ongoing Paragraph IV litigation, with efforts to resolve cases quickly and positively.

• Patent protection for Firdapse extends to February 2037, and for Agamree to July 2040.

Firdapse performance and growth drivers

• Growth driven by both price (5%) and volume (10%), with 50% of new patients from an identified pipeline and 50% de novo.

• 40% of patients were on the maximum labeled dose; new higher dose expected to increase average dose by 5–10% over the next 3–4 quarters.

• Patient mix is about 80% non-tumor and 20% tumor LEMS, with significant upside in the tumor segment.

• Simple diagnostic test for tumor LEMS offers opportunity to improve care and expand market.

• Global expansion ongoing, with approvals in Canada and expected approval in Japan, and plans for APAC and LATAM via partnerships.